LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

LLY

1,149.14

-0.93%↓

JNJ

236.12

+1.8%↑

ABBV

226.33

+1.84%↑

UNH

410.34

+1.2%↑

MRK

119.87

-0.03%↓

Strona główna・Stock List・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Open

SectorHealthcare

1.37 -2.84

Buy Sell

Overview

Share price change

24h

Current

Min

1.35

Max

1.43

Key metrics
By Trading Economics
Income	32M -8.3M
Sales	-7.5M 37M
EPS	-0.12
Profit margin	-22.258
Employees	485
EBITDA	509K -38M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+72.46% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	9.5M 491M
Previous open	4.21
Previous close	1.37

News Sentiment

By Acuity

50%

161 / 344 Ranking in Healthcare

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 cze 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 cze 2026, 15:41 UTC

Major Market Movers

American Battery Shares Jump on Energy Department Victory

8 cze 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 cze 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 cze 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 21:57 UTC

Acquisitions, Mergers, Takeovers

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 cze 2026, 21:56 UTC

Acquisitions, Mergers, Takeovers

Salesforce Agrees to Buy m3ter

8 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8 cze 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 cze 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 cze 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8 cze 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 cze 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 cze 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 cze 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 cze 2026, 16:55 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 cze 2026, 16:54 UTC

Acquisitions, Mergers, Takeovers

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 cze 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 cze 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 cze 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 cze 2026, 16:03 UTC

Acquisitions, Mergers, Takeovers

Orange Bought Stake From Lorca

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 cze 2026, 16:01 UTC

Acquisitions, Mergers, Takeovers

Orange Acquires 100% Ownership of MasOrange

8 cze 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8 cze 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 cze 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 cze 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

72.46% upside

12 Months Forecast

Average 2.38 USD 72.46%

High 3 USD

Low 1.5 USD

Based on 4 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pacific Biosciences of California Inc - Dist in the past 3 months.

Sentiment

By Acuity

161 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.